Assetmark, Inc Concert Pharmaceuticals, Inc. Transaction History

Assetmark, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$5.88 - $12.35 $329 - $691	-56 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$9.44 - $13.12 $94 - $131	10 Added 21.74%	56 $1,000
Q1 2019 May 14, 2019	SELL	$12.07 - $17.54 $627 - $912	-52 Reduced 53.06%	46 $1,000
Q4 2018 Feb 13, 2019	SELL	$11.25 - $16.17 $258 - $371	-23 Reduced 19.01%	98 $1,000
Q3 2018 Nov 13, 2018	SELL	$12.82 - $17.88 $128 - $178	-10 Reduced 7.63%	121 $2,000
Q1 2018 May 16, 2018	BUY	$19.24 - $28.03 $519 - $756	27 Added 25.96%	131 $3,000
Q4 2017 Feb 13, 2018	BUY	$13.96 - $29.05 $1,451 - $3,021	104	104 $3,000

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.